Faculty

Back to Index
David B. Agus, MD
Professor of Medicine
Director, Lawrence J. Ellison Institute For Transformative Medicine of Usc
Director, USC Center For Applied Molecular Medicine
Medicine
WMB 9033 Wilshire Blvd Health Sciences Campus Beverly Hills
+1 310 272 7640

Overview

Dr. David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the founding director of USC’s Lawrence J. Ellison Institute for Transformative Medicine.   Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs, and directs a National Cancer Institute Physical Sciences in Oncology Center at USC.  He is a medical oncologist and the co-founder of several personalized medicine companies. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare, serving in leadership roles at the World Economic Forum, among other prestigious organizations. Dr. Agus’ first book called “The End of Illness” was published in 2012 and is a New York Times #1 and international best seller and was the subject of a PBS series, and his most recent books “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are also New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital.

Awards

American Cancer Society: Physician Research Award

Sloan-Kettering Institute: Clinical Scholar Award

CaP CURE: Young Investigator Award

American Society of Clinical Oncology: Fellowship Award

HealthNetwork Foundation: Excellence Award

Geoffrey Beene Foundation: Rock Stars of Scienceâ„¢, 2009

Biotech Humanitarian Award: Selected Judge, 2009

Geoffrey Beene Foundation: Rock Stars of Science™, 2009

Sloan-Kettering Institute: Clinical Scholar Award, 1996

American Cancer Society: Physician Research Award, 1996-2001

CaP CURE : Young Investigator Award, 1998-2001

HealthNetwork Foundation: Excellence Award, 2008

American Cancer Society: Clinical Oncology Fellowship Award, 1994

USC Association of Trojan Leagues: Outstanding Service Award, 2013

Geoffrey Beene Foundation: contactPhone, 2009

HealthNetwork Foundation: contactPhone, 2008

CaP CURE : contactPhone, 1998-2001

American Cancer Society: contactPhone, 1996-2001

Sloan-Kettering Institute: contactPhone, 1996

American Cancer Society: contactPhone, 1994

USC Association of Trojan Leagues: contactPhone, 2013

Biotech Humanitarian Award: contactPhone, 2009

Sloan-Kettering Institute: start date, 1996

USC Association of Trojan Leagues: start date, 2013

American Cancer Society: start date, 1996-2001

HealthNetwork Foundation: start date, 2008

CaP CURE : start date, 1998-2001

Geoffrey Beene Foundation: start date, 2009

American Cancer Society: full name, 1996-2001

American Cancer Society: full name, 1994

HealthNetwork Foundation: full name, 2008

Geoffrey Beene Foundation: full name, 2009

Sloan-Kettering Institute: full name, 1996

Biotech Humanitarian Award: full name, 2009

CaP CURE : full name, 1998-2001

USC Association of Trojan Leagues: full name, 2013

USC Association of Trojan Leagues: ORNG Application Instance Data value, 2013

Sloan-Kettering Institute: ORNG Application Instance Data value, 1996

Biotech Humanitarian Award: ORNG Application Instance Data value, 2009

American Cancer Society: ORNG Application Instance Data value, 1994

American Cancer Society: ORNG Application Instance Data value, 1996-2001

CaP CURE : ORNG Application Instance Data value, 1998-2001

Geoffrey Beene Foundation: ORNG Application Instance Data value, 2009

HealthNetwork Foundation: ORNG Application Instance Data value, 2008

Geoffrey Beene Foundation: Tag Editor, 2009

Biotech Humanitarian Award: Tag Editor, 2009

Sloan-Kettering Institute: Tag Editor, 1996

American Cancer Society: Tag Editor, 1996-2001

HealthNetwork Foundation: Tag Editor, 2008

CaP CURE : Tag Editor, 1998-2001

American Cancer Society: Tag Editor, 1994

USC Association of Trojan Leagues: is primary position, 2013

CaP CURE : is primary position, 1998-2001

American Cancer Society: is primary position, 1996-2001

Biotech Humanitarian Award: is primary position, 2009

Geoffrey Beene Foundation: is primary position, 2009

Sloan-Kettering Institute: is primary position, 1996

American Cancer Society: is primary position, 1994

CaP CURE : last name, 1998-2001

Geoffrey Beene Foundation: last name, 2009

USC Association of Trojan Leagues: last name, 2013

Sloan-Kettering Institute: last name, 1996

American Cancer Society: last name, 1994

American Cancer Society: last name, 1996-2001

HealthNetwork Foundation: last name, 2008

Biotech Humanitarian Award: last name, 2009

CaP CURE : ORNG Application URL, 1998-2001

HealthNetwork Foundation: ORNG Application URL, 2008

Biotech Humanitarian Award: ORNG Application URL, 2009

Sloan-Kettering Institute: ORNG Application URL, 1996

American Cancer Society: ORNG Application URL, 1996-2001

American Cancer Society: ORNG Application URL, 1994

USC Association of Trojan Leagues: ORNG Application URL, 2013

Geoffrey Beene Foundation: ORNG Application URL, 2009

HealthNetwork Foundation: In The News, 2008

USC Association of Trojan Leagues: In The News, 2013

Sloan-Kettering Institute: In The News, 1996

Geoffrey Beene Foundation: In The News, 2009

American Cancer Society: In The News, 1996-2001

CaP CURE : In The News, 1998-2001

American Cancer Society: In The News, 1994

Biotech Humanitarian Award: In The News, 2009

Sloan-Kettering Institute: Department, 1996

CaP CURE : Department, 1998-2001

American Cancer Society: Department, 1994

Geoffrey Beene Foundation: Department, 2009

USC Association of Trojan Leagues: Department, 2013

Biotech Humanitarian Award: Department, 2009

American Cancer Society: Department, 1996-2001

HealthNetwork Foundation: Department, 2008

Geoffrey Beene Foundation: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 2009

American Cancer Society: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 1996-2001

Sloan-Kettering Institute: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 1996

HealthNetwork Foundation: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 2008

American Cancer Society: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 1994

CaP CURE : http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 1998-2001

Biotech Humanitarian Award: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 2009

USC Association of Trojan Leagues: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-123, 2013

USC Association of Trojan Leagues: sort order, 2013

Geoffrey Beene Foundation: sort order, 2009

Sloan-Kettering Institute: sort order, 1996

HealthNetwork Foundation: sort order, 2008

CaP CURE : sort order, 1998-2001

American Cancer Society: sort order, 1994

Biotech Humanitarian Award: sort order, 2009

Biotech Humanitarian Award: Person, 2009

HealthNetwork Foundation: Person, 2008

American Cancer Society: Person, 1994

American Cancer Society: Person, 1996-2001

Sloan-Kettering Institute: Person, 1996

Geoffrey Beene Foundation: Person, 2009

CaP CURE : Person, 1998-2001

USC Association of Trojan Leagues: Organization, 2013

CaP CURE : Organization, 1998-2001

Biotech Humanitarian Award: Organization, 2009

Geoffrey Beene Foundation: Organization, 2009

American Cancer Society: Organization, 1994

American Cancer Society: Organization, 1996-2001

Sloan-Kettering Institute: Organization, 1996

HealthNetwork Foundation: Organization, 2008

HealthNetwork Foundation: preRequisites, 2008

USC Association of Trojan Leagues: preRequisites, 2013

American Cancer Society: preRequisites, 1994

Sloan-Kettering Institute: preRequisites, 1996

American Cancer Society: preRequisites, 1996-2001

Biotech Humanitarian Award: preRequisites, 2009

CaP CURE : preRequisites, 1998-2001

Geoffrey Beene Foundation: preRequisites, 2009

Biotech Humanitarian Award: email address, 2009

CaP CURE : email address, 1998-2001

Geoffrey Beene Foundation: email address, 2009

USC Association of Trojan Leagues: email address, 2013

HealthNetwork Foundation: email address, 2008

American Cancer Society: email address, 1994

American Cancer Society: email address, 1996-2001

Biotech Humanitarian Award: start date, 2009

American Cancer Society: start date, 1994

American Cancer Society: award conferred by, 1996-2001

Biotech Humanitarian Award: award conferred by, 2009

Geoffrey Beene Foundation: award conferred by, 2009

American Cancer Society: award conferred by, 1994

Sloan-Kettering Institute: award conferred by, 1996

CaP CURE : award conferred by, 1998-2001

USC Association of Trojan Leagues: award conferred by, 2013

HealthNetwork Foundation: award conferred by, 2008

American Cancer Society: Required Scholarly Project Mentor, 1996-2001

USC Association of Trojan Leagues: Required Scholarly Project Mentor, 2013

American Cancer Society: Required Scholarly Project Mentor, 1994

Sloan-Kettering Institute: Required Scholarly Project Mentor, 1996

HealthNetwork Foundation: Required Scholarly Project Mentor, 2008

CaP CURE : Required Scholarly Project Mentor, 1998-2001

Geoffrey Beene Foundation: Required Scholarly Project Mentor, 2009

American Cancer Society: Person ID, 1996-2001

American Cancer Society: Person ID, 1994

Biotech Humanitarian Award: Person ID, 2009

Sloan-Kettering Institute: Person ID, 1996

HealthNetwork Foundation: Person ID, 2008

CaP CURE : Person ID, 1998-2001

Geoffrey Beene Foundation: Person ID, 2009

USC Association of Trojan Leagues: Person ID, 2013

American Cancer Society: end date, 1996-2001

Biotech Humanitarian Award: MediaLinks, 2009

USC Association of Trojan Leagues: MediaLinks, 2013

HealthNetwork Foundation: MediaLinks, 2008

American Cancer Society: MediaLinks, 1994

Sloan-Kettering Institute: MediaLinks, 1996

CaP CURE : end date, 1998-2001

Geoffrey Beene Foundation: MediaLinks, 2009

American Cancer Society: Keck School of Medicine of USC, 1994

American Cancer Society: Keck School of Medicine of USC, 1996-2001

USC Association of Trojan Leagues: Keck School of Medicine of USC, 2013

Geoffrey Beene Foundation: Keck School of Medicine of USC, 2009

Biotech Humanitarian Award: Keck School of Medicine of USC, 2009

HealthNetwork Foundation: Keck School of Medicine of USC, 2008

Sloan-Kettering Institute: Keck School of Medicine of USC, 1996

CaP CURE : Keck School of Medicine of USC, 1998-2001

American Cancer Society: activeProjects, 1996-2001

USC Association of Trojan Leagues: activeProjects, 2013

CaP CURE : activeProjects, 1998-2001

American Cancer Society: activeProjects, 1994

Sloan-Kettering Institute: activeProjects, 1996

Biotech Humanitarian Award: activeProjects, 2009

Geoffrey Beene Foundation: activeProjects, 2009

HealthNetwork Foundation: is primary position, 2008

Geoffrey Beene Foundation: Professor, 2009

CaP CURE : Professor, 1998-2001

American Cancer Society: Professor, 1994

American Cancer Society: Professor, 1996-2001

HealthNetwork Foundation: Professor, 2008

Biotech Humanitarian Award: Professor, 2009

Sloan-Kettering Institute: Professor, 1996

USC Association of Trojan Leagues: Professor, 2013

CaP CURE : Faculty Rank, 1998-2001

American Cancer Society: Faculty Rank, 1996-2001

Sloan-Kettering Institute: Faculty Rank, 1996

Biotech Humanitarian Award: Faculty Rank, 2009

USC Association of Trojan Leagues: Faculty Rank, 2013

Geoffrey Beene Foundation: Faculty Rank, 2009

HealthNetwork Foundation: Faculty Rank, 2008

American Cancer Society: Faculty Rank, 1994

Biotech Humanitarian Award: award or honor for, 2009

CaP CURE : award or honor for, 1998-2001

Sloan-Kettering Institute: award or honor for, 1996

American Cancer Society: award or honor for, 1996-2001

American Cancer Society: award or honor for, 1994

Geoffrey Beene Foundation: award or honor for, 2009

USC Association of Trojan Leagues: award or honor for, 2013

HealthNetwork Foundation: award or honor for, 2008

American Cancer Society: position in organization, 1994

HealthNetwork Foundation: position in organization, 2008

Geoffrey Beene Foundation: position in organization, 2009

USC Association of Trojan Leagues: position in organization, 2013

Sloan-Kettering Institute: position in organization, 1996

Biotech Humanitarian Award: position in organization, 2009

CaP CURE : position in organization, 1998-2001

American Cancer Society: position in organization, 1996-2001

Biotech Humanitarian Award: person in primary position, 2009

Geoffrey Beene Foundation: person in primary position, 2009

CaP CURE : person in primary position, 1998-2001

American Cancer Society: person in primary position, 1994

Sloan-Kettering Institute: person in primary position, 1996

American Cancer Society: person in primary position, 1996-2001

HealthNetwork Foundation: person in primary position, 2008

USC Association of Trojan Leagues: person in primary position, 2013

USC Association of Trojan Leagues: Person, 2013

Geoffrey Beene Foundation: contactEmail, 2009

Biotech Humanitarian Award: contactEmail, 2009

Sloan-Kettering Institute: contactEmail, 1996

American Cancer Society: contactEmail, 1994

American Cancer Society: contactEmail, 1996-2001

USC Association of Trojan Leagues: contactEmail, 2013

HealthNetwork Foundation: contactEmail, 2008

CaP CURE : contactEmail, 1998-2001

American Cancer Society: Professor of Medicine, 1996-2001

HealthNetwork Foundation: Professor of Medicine, 2008

Geoffrey Beene Foundation: Professor of Medicine, 2009

Biotech Humanitarian Award: Professor of Medicine, 2009

American Cancer Society: Professor of Medicine, 1994

CaP CURE : Professor of Medicine, 1998-2001

Sloan-Kettering Institute: Professor of Medicine, 1996

USC Association of Trojan Leagues: Professor of Medicine, 2013

American Cancer Society: studentMentor, 1996-2001

CaP CURE : studentMentor, 1998-2001

Biotech Humanitarian Award: studentMentor, 2009

Sloan-Kettering Institute: studentMentor, 1996

USC Association of Trojan Leagues: studentMentor, 2013

HealthNetwork Foundation: studentMentor, 2008

American Cancer Society: studentMentor, 1994

Geoffrey Beene Foundation: studentMentor, 2009

USC Association of Trojan Leagues: Tag Editor, 2013

American Cancer Society: ORNG Application Instance for Person, 1996-2001

Biotech Humanitarian Award: ORNG Application Instance for Person, 2009

USC Association of Trojan Leagues: ORNG Application Instance for Person, 2013

CaP CURE : ORNG Application Instance for Person, 1998-2001

Geoffrey Beene Foundation: ORNG Application Instance for Person, 2009

American Cancer Society: ORNG Application Instance for Person, 1994

HealthNetwork Foundation: ORNG Application Instance for Person, 2008

Sloan-Kettering Institute: ORNG Application Instance for Person, 1996

HealthNetwork Foundation: has ORNG Application Instance Data, 2008

Biotech Humanitarian Award: has ORNG Application Instance Data, 2009

American Cancer Society: has ORNG Application Instance Data, 1994

Geoffrey Beene Foundation: has ORNG Application Instance Data, 2009

CaP CURE : has ORNG Application Instance Data, 1998-2001

American Cancer Society: has ORNG Application Instance Data, 1996-2001

Sloan-Kettering Institute: has ORNG Application Instance Data, 1996

USC Association of Trojan Leagues: has ORNG Application Instance Data, 2013

American Cancer Society: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 1996-2001

HealthNetwork Foundation: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 2008

Geoffrey Beene Foundation: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 2009

American Cancer Society: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 1994

USC Association of Trojan Leagues: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 2013

CaP CURE : http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 1998-2001

Biotech Humanitarian Award: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 2009

Sloan-Kettering Institute: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 1996

CaP CURE : http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 1998-2001

USC Association of Trojan Leagues: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 2013

Geoffrey Beene Foundation: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 2009

Sloan-Kettering Institute: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 1996

Biotech Humanitarian Award: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 2009

American Cancer Society: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 1994

American Cancer Society: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 1996-2001

HealthNetwork Foundation: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-122, 2008

CaP CURE : MediaLinks, 1998-2001

American Cancer Society: MediaLinks, 1996-2001

Sloan-Kettering Institute: Medicine, 1996

CaP CURE : Medicine, 1998-2001

American Cancer Society: Medicine, 1996-2001

HealthNetwork Foundation: Medicine, 2008

Geoffrey Beene Foundation: Medicine, 2009

Biotech Humanitarian Award: Medicine, 2009

USC Association of Trojan Leagues: Award or Honor Receipt, 2013

American Cancer Society: Award or Honor Receipt, 1996-2001

Geoffrey Beene Foundation: Award or Honor Receipt, 2009

Sloan-Kettering Institute: Award or Honor Receipt, 1996

HealthNetwork Foundation: Award or Honor Receipt, 2008

American Cancer Society: Award or Honor Receipt, 1994

CaP CURE : Award or Honor Receipt, 1998-2001

Biotech Humanitarian Award: Award or Honor Receipt, 2009

American Cancer Society: tags, 1996-2001

USC Association of Trojan Leagues: tags, 2013

American Cancer Society: tags, 1994

Sloan-Kettering Institute: tags, 1996

HealthNetwork Foundation: tags, 2008

CaP CURE : tags, 1998-2001

Geoffrey Beene Foundation: tags, 2009

Biotech Humanitarian Award: tags, 2009

HealthNetwork Foundation: preferred title, 2008

Geoffrey Beene Foundation: preferred title, 2009

American Cancer Society: preferred title, 1994

CaP CURE : preferred title, 1998-2001

Biotech Humanitarian Award: preferred title, 2009

Sloan-Kettering Institute: preferred title, 1996

American Cancer Society: preferred title, 1996-2001

USC Association of Trojan Leagues: preferred title, 2013

Biotech Humanitarian Award: Required Scholarly Project Mentor, 2009

Sloan-Kettering Institute: researchArea, 1996

HealthNetwork Foundation: researchArea, 2008

USC Association of Trojan Leagues: researchArea, 2013

American Cancer Society: researchArea, 1996-2001

Biotech Humanitarian Award: researchArea, 2009

Geoffrey Beene Foundation: researchArea, 2009

American Cancer Society: researchArea, 1994

CaP CURE : researchArea, 1998-2001

Sloan-Kettering Institute: email address, 1996

Ellis Island Medal of Honor: ORNG Application Instance Data value, 2017

American College of Physicians: ORNG Application Instance Data value, 2016

American College of Physicians: Faculty Rank, 2016

Ellis Island Medal of Honor: Faculty Rank, 2017

Ellis Island Medal of Honor: tags, 2017

American College of Physicians: tags, 2016

Biotech Humanitarian Award: photo, 2009

American Cancer Society: photo, 1994

American Cancer Society: photo, 1996-2001

Ellis Island Medal of Honor: photo, 2017

USC Association of Trojan Leagues: photo, 2013

Sloan-Kettering Institute: photo, 1996

HealthNetwork Foundation: photo, 2008

Geoffrey Beene Foundation: photo, 2009

American College of Physicians: photo, 2016

American College of Physicians: RequiredScholarlyProjectMentor, 2016

American Cancer Society: RequiredScholarlyProjectMentor, 1994

Sloan-Kettering Institute: RequiredScholarlyProjectMentor, 1996

Biotech Humanitarian Award: RequiredScholarlyProjectMentor, 2009

Geoffrey Beene Foundation: RequiredScholarlyProjectMentor, 2009

HealthNetwork Foundation: RequiredScholarlyProjectMentor, 2008

Ellis Island Medal of Honor: RequiredScholarlyProjectMentor, 2017

American Cancer Society: RequiredScholarlyProjectMentor, 1996-2001

USC Association of Trojan Leagues: RequiredScholarlyProjectMentor, 2013

Geoffrey Beene Foundation: HR job title, 2009

Sloan-Kettering Institute: HR job title, 1996

HealthNetwork Foundation: HR job title, 2008

American Cancer Society: HR job title, 1994

Ellis Island Medal of Honor: HR job title, 2017

Biotech Humanitarian Award: HR job title, 2009

American Cancer Society: HR job title, 1996-2001

American College of Physicians: HR job title, 2016

USC Association of Trojan Leagues: HR job title, 2013

American College of Physicians: ORNG Application URL, 2016

Ellis Island Medal of Honor: ORNG Application URL, 2017

Ellis Island Medal of Honor: Organization, 2017

American College of Physicians: Organization, 2016

Geoffrey Beene Foundation: first name, 2009

American College of Physicians: first name, 2016

HealthNetwork Foundation: first name, 2008

American Cancer Society: first name, 1994

Ellis Island Medal of Honor: first name, 2017

Sloan-Kettering Institute: first name, 1996

Biotech Humanitarian Award: first name, 2009

USC Association of Trojan Leagues: first name, 2013

Ellis Island Medal of Honor: position in organization, 2017

American College of Physicians: position in organization, 2016

Biotech Humanitarian Award: has faculty rank, 2009

American Cancer Society: has faculty rank, 1996-2001

Sloan-Kettering Institute: has faculty rank, 1996

HealthNetwork Foundation: has faculty rank, 2008

American Cancer Society: has faculty rank, 1994

American College of Physicians: has faculty rank, 2016

Ellis Island Medal of Honor: has faculty rank, 2017

USC Association of Trojan Leagues: has faculty rank, 2013

American College of Physicians: start date, 2016

American College of Physicians: position in department, 2016

Ellis Island Medal of Honor: position in department, 2017

Sloan-Kettering Institute: position in department, 1996

HealthNetwork Foundation: position in department, 2008

American Cancer Society: position in department, 1994

Biotech Humanitarian Award: position in department, 2009

American Cancer Society: position in department, 1996-2001

Geoffrey Beene Foundation: position in department, 2009

USC Association of Trojan Leagues: position in department, 2013

Ellis Island Medal of Honor: start date, 2017

Ellis Island Medal of Honor: ORNG Application Instance for Person, 2017

American College of Physicians: ORNG Application Instance for Person, 2016

American College of Physicians: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 2016

Ellis Island Medal of Honor: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1761-115, 2017

American College of Physicians: MediaLinks, 2016

Ellis Island Medal of Honor: MediaLinks, 2017

American College of Physicians: has ORNG Application Instance Data, 2016

Ellis Island Medal of Honor: has ORNG Application Instance Data, 2017

Publications

Single cell dynamic phenotyping. Sci Rep. 2016 Oct 06; 6:34785. View in: PubMed

Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. View in: PubMed

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016; 11(11):e0166103. View in: PubMed

Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016; 6:22435. View in: PubMed

THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW. Fortune. 2016 Jan 1; 173(1):90-3. View in: PubMed

A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016; 6:29752. View in: PubMed

Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23; 385(9982):2118-9. View in: PubMed

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. View in: PubMed

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 1; 33(7):723-31. View in: PubMed

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. View in: PubMed

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: PubMed

Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2014 Mar 1; 20(5):1335-44. View in: PubMed

Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. View in: PubMed

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. View in: PubMed

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. View in: PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. View in: PubMed

Perspective: Meeting of minds. Nature. 2012 Nov 22; 491(7425):S61. View in: PubMed

Reframe the health debate. Fortune. 2012 Oct 29; 166(7):22. View in: PubMed

A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct 10; 30(10):918-20. View in: PubMed

Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. View in: PubMed

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. View in: PubMed

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. View in: PubMed

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 5; 8(6):2069-79. View in: PubMed

Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. View in: PubMed

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55. View in: PubMed

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. View in: PubMed

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. View in: PubMed

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20. View in: PubMed

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 1; 70(5):1989-99. View in: PubMed

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. View in: PubMed

Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501. View in: PubMed

Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. View in: PubMed

ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 1; 24(21):2534-6. View in: PubMed

Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. View in: PubMed

Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. View in: PubMed

The current state of preclinical prostate cancer animal models. Prostate. 2008 May 1; 68(6):629-39. View in: PubMed

Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 1; 13(7):1979-86. View in: PubMed

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81. View in: PubMed

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. View in: PubMed

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007; 7:142. View in: PubMed

Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. View in: PubMed

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. View in: PubMed

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8. View in: PubMed

A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82. View in: PubMed

Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. View in: PubMed

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. View in: PubMed

CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 1; 61(3):228-35. View in: PubMed

PPARgamma signaling: one size fits all? Cell Cycle. PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. View in: PubMed

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. View in: PubMed

Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. View in: PubMed

Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. View in: PubMed

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1; 22(3):537-56. View in: PubMed

Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. View in: PubMed

Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. View in: PubMed

Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 6; 94(21):1641-7. View in: PubMed

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31. View in: PubMed

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37. View in: PubMed

TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. View in: PubMed

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55. View in: PubMed

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93. View in: PubMed

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279. View in: PubMed

Powered bySC CTSI